Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chymotrypsin→

Chymotrypsin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9004-07-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Proteolytic enzymeserine endopeptidase
Mechanism of action
Hydrolyses peptide bonds adjacent to aromatic amino acids, including phenylalanine, tyrosine and tryptophan. Pharmaceutical preparations are used for local or systemic proteolytic effects depending on formulation.
Indications / reported uses
  • Used in selected countries as an enzyme preparation for reduction of local oedema or as an adjunct in wound-care or ophthalmic procedures; clinical indications and evidence depend on the specific formulation and route

Sources: NLM MeSH — Chymotrypsin · PubMed — Chymotrypsin therapeutic preparations · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chymotrypsin Environmental Risk Assessment (ERA) (the Chymotrypsin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.